Exozymes Inc. (EXOZ) stock
EXOZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.83−0.17 (-4.25%)
Close on Nov 13, 2026Market cap $35.55MP/E –Yield –
Exozymes r&d expenses
Research and development expenses are spending on new products and technology.
Exozymes's R&D Expenses for the twelve months ending Sep 30, 2026 was $5.29M, up 64.0% year over year. For fiscal 2025 it was $3.71M, up 98.4% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.71M | +98.4% |
| FY2024 | Dec 31, 2024 | $1.87M | +254.3% |
| FY2023 | Dec 31, 2023 | $527.48K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.62M | +32.9% |
| Q2 FY2026 | Jun 30, 2026 | $1.44M | +79.1% |
| Q1 FY2026 | Mar 31, 2026 | $1.12M | +95.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.11M | +76.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.22M | +68.2% |
| Q2 FY2025 | Jun 30, 2025 | $802.99K | +238.3% |
| Q1 FY2025 | Mar 31, 2025 | $575.02K | +107.2% |
| Q4 FY2024 | Dec 31, 2024 | $630.30K | +36.9% |
| Q3 FY2024 | Sep 30, 2024 | $723.49K | +2489.8% |
| Q2 FY2024 | Jun 30, 2024 | $237.40K | – |
| Q1 FY2024 | Mar 31, 2024 | $277.58K | – |
| Q4 FY2023 | Dec 31, 2023 | $460.39K | – |
| Q3 FY2023 | Sep 30, 2023 | $27.94K | – |
See a number that looks wrong?